John Furey
CIK 1691218 · Chief Operating Officer · last filed 2025-06-16
John Furey is a Chief Operating Officer who has filed 14 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for PCVX, was dated Jun 16, 2025. Across all open-market trades the lifetime net is −$3.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $144.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$144.3K
4
14
-$3.20M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCVX | Director | 3,041 | $47.46 | $144.3K | $0 | 2 | 2025-06-16 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | — | $0.06 | — | $0 | 5 | 2024-07-01 |
| ASND | Director | — | $218.06 | — | $0 | 1 | 2019-07-03 |
| Spark Therapeutics, Inc. (ONCE) Delisted | Chief Operating Officer | 18 | — | — | -$3.20M | 6 | 2018-04-24 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-16 | PCVX | Grant (A) | +3,041 | $0 | EDGAR |
| 2024-07-03 | PCVX | Grant (A) | — | $0 | EDGAR |
| 2024-07-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-03 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-07-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-02 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-07-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-03 | ASND | Grant (A) | — | $0 | EDGAR |
| 2018-04-24 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$220.2K | EDGAR |
| 2018-04-19 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$435.3K | EDGAR |